-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Alnylam Pharmaceuticals, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2017 to Q1 2025.
- Alnylam Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2025 was $9.64M, a 2023% increase year-over-year.
- Alnylam Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was -$107M, a 14874% decline from 2023.
- Alnylam Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$713K, a 50.2% increase from 2022.
- Alnylam Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$1.43M, a 48.2% increase from 2021.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)